Liver failure
Conditions
Interventions
Experimental group:All the enrolled subjects received a total of 5 treatments. In the experimental group, the examination indexes and treatment conditions were evaluated after 3 times of bioartificial
Control group:The control group completed 3 times of physical artificial liver treatment within 1 week and evaluated the examination indexes and treatment status. If the treatment was
effective, the t
Sponsors
Zhongnan Hospital of Wuhan University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) The patients or their legal representatives could understand and voluntarily sign the informed consent, communicate with the researchers, understand and cooperate with the implementation of the plan. (2) Age of 18-65 years old, regardless of gender. (3) patients with early and middle stage acute, subacute, acute-on-chronic, and subacute chronic liver failure caused by various reasons (progressive deepening of jaundice (serum total bilirubin > 171µmol/L or a daily increase in total bilirubin =17.1µmol/L; Bleeding tendency, PTA= 40%) . (4) patients with advanced liver failure waiting for donor before liver transplantation, rejection after liver transplantation, and non-functional phase of transplanted liver. (5) The clinical diagnosis did not meet the criteria of severe hepatitis or liver failure, but the comprehensive judgment showed a significant tendency to develop into liver failure (serum total bilirubin > 85.5µmol/L and serum total bilirubin increased =17.1µmol/L daily; Significant bleeding tendency, PTA= 50%). (6) hyperbilirubinemia caused by various reasons (serum total bilirubin > 171µmol/L) and ineffective medical treatment.
Exclusion criteria
Exclusion criteria: (1) Patients with severe active bleeding or disseminated intravascular coagulation. (2) unstable cardiac or cerebral infarction; (3) extrahepatic malignant tumors that are difficult to cure radically. (4) patients with severe hypotension or systemic circulatory failure such as shock. (5) In the late stage of the disease, there were irreversible respiratory failure, severe cerebral edema with cerebral hernia and other endangered symptoms. (6) severe systemic infection, including pulmonary infection, sepsis, abdominal infection, intracranial infection, and active tuberculosis. (7) acquired human immunodeficiency syndrome virus (HIV) infection. (8) Severe allergies to blood products or drugs used in the treatment, such as plasma, heparin or protamine. (9) pregnant women. (10) Psychiatric patients with a history of mental illness or under treatment, poor compliance, inability to cooperate with research or follow up, and other conditions deemed unsuitable for treatment by doctors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver function and kidney function;Coagulation function;Survival time; | — |
Secondary
| Measure | Time frame |
|---|---|
| MELD score;Child Pugh rating; | — |
Countries
China
Contacts
Public ContactYe qifa
Zhongnan Hospital of Wuhan University
Outcome results
None listed